Can you get tirzepatide from a compounding pharmacy?
Some pharmacies or clinics may supply compounded versions of medicines like tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) to patients, but the FDA has issued safety warnings about this practice. Concerns have risen over active ingredients, side effects and labeling of these compounded products.
Tirzepatide injection is only available as a prescription brand name product. It comes in pre-filled single-dose pens vials (Mounjaro) and / or single-dose pens (Zepbound), according to Eli Lilly, the manufacturer.
- Zepbound is approved by the FDA for weight loss in adults with obesity or who are overweight and have weight-related medical problems. Zepbound helps you to lose weight and maintain weight loss and should be combined with a reduced-calorie diet and exercise. It is also approved to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.
- Mounjaro is used to help lower blood sugar in adults with type 2 diabetes and is also used together with diet and exercise.
Some people may receive a prescription for compounded medicine because they need a special formulation, to help save costs, or due to a drug shortage in their area. According to the drug shortages list from the FDA, injectable prescription tirzepatide is now available commercially, although shortages have occurred with this product and others like it in the past.
Related: How does Zepbound help treat sleep apnea?
Is compounded tirzepatide safe?
The FDA does not review compounded versions of prescription medications, including tirzepatide, for safety, effectiveness or quality. In addition, Eli Lilly, the manufacturer of tirzepatide states that they cannot validate the safety or effectiveness of products claiming to contain tirzepatide that are not their branded product (brand names: Mounjaro and Zepbound).
Eli Lilly has stated that they have filed lawsuits to protect patient safety and stop the unlawful sales of compounded tirzepatide, a non-FDA approved and fraudulent product.
Semaglutide example
In May 2023 the FDA raised some concerns about another compounded incretin mimetic, semaglutide (Ozempic and Wegovy) from Novo Nordisk.
According to the FDA there have been reports of side effects (“adverse events”) in patients who have used compounded version of semaglutide, a drug similar to tirzepatide and used to treat patients with type 2 diabetes, for cardiovascular risk reduction, and for weight loss management.
The FDA also reported that some compounding pharmacies were using different salt forms of semaglutide as the active ingredient. These include semaglutide acetate and semaglutide sodium, products that are not approved by the FDA and are different from the active ingredients found in Ozempic or Wegovy.
There are no generic options for tirzepatide in the U.S. and the active ingredient for compounding is not available from the manufacturer.
Novo Nordisk is also pursuing legal action against compounding pharmacies for selling adulterated and misbranded compounded drugs claiming to contain semaglutide.
Related questions
- Ozempic Side Effects to Watch For
- 6 Wegovy side effects you need to be aware of
- How do Ozempic, Mounjaro, Wegovy, Zepbound compare for weight loss?
What exactly is drug compounding?
Drug compounding is a legal and a well-accepted practice in the United States, often done by licensed pharmacists or other healthcare providers. Drug compounding is the process of combining, mixing, or changing ingredients to create a medication specific for the needs of an individual patient.
A compounded version of an approved drug may be formulated if it meets certain conditions in the Federal Food, Drug and Cosmetic (FD&C) Act. For example, if an approved drug is in shortage, a compounded version can be legally prepared. However, compounded drugs are not FDA-approved, and the agency does not verify the safety or effectiveness of compounded drugs.
Compounded medications require a prescription from a healthcare provider. Licensed compounding pharmacies in the U.S. can legally prepare compounded medications when adhering to guidelines from the FDA and their State Board of Pharmacy. Patients should only obtain medicines from state-licensed pharmacies or facilities registered with the FDA.
However, concerns have been raised about some compounding practices in the past, including sterility and other quality issues.
What can patients do?
Speak to your healthcare provider about the availability of FDA-approved, prescription injectable tirzepatide (Mounjaro or Zepbound) in your area. If there is a shortage, discuss what options you have for the safe use of a prescription drug for your condition. The FDA states that a patient should not use a compounded product if an approved medication like Mounjaro or Zepbound is available.
If you think you have received counterfeit tirzepatide or accessed it from an unauthorized source, contact your healthcare provider. Counterfeit drugs may contain the wrong ingredients, too little or too much drug, dangerous compounds, or no active ingredient at all.
Patients and healthcare providers can also report counterfeit tirzepatide by calling Eli Lilly at 1-800-545-5979.
FDA also encourages health care professionals, patients, and compounders to report adverse events or quality problems with these or any medications to FDA’s MedWatch Adverse Event Reporting program.
This is not all the information you need to know about compounded tirzepatide for safe and effective use and does not take the place of your doctor’s directions. Discuss this information and any questions you have with your doctor or other health care provider.
References
- FDA Approves First Medication for Obstructive Sleep Apnea. US Food and Drug Administration (FDA). Dec. 28, 2024. Press Announcements. Accessed Dec. 23, 2024 at https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
- Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. US Food and Drug Administration (FDA). October 31, 2023. Accessed Dec. 14, 2023 at https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
- FDA Drug Shortages. US Food and Drug Administration (FDA). Accessed Dec. 14, 2023 https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
- Lilly Statement on Mounjaro® (tirzepatide) Compounding Litigation. Press release. Sept. 19, 2023. Accessed Dec. 14, 2023 at https://investor.lilly.com/news-releases/news-release-details/lilly-statement-mounjaror-tirzepatide-compounding-litigation
- Zepbound (tirzepatide) prescribing information. Eli Lilly & Co. Indianapolis, IN. Accessed Dec. 14, 2023 at https://uspl.lilly.com/zepbound/zepbound.html#pi
- Mounjaro (tirzepatide) prescribing information. Eli Lilly & Co. Indianapolis, IN. Accessed Dec. 14, 2023 at https://uspl.lilly.com/mounjaro/mounjaro.html#s7
- Novo Nordisk takes additional legal actions to help protect US patients from potentially unsafe and ineffective compounded drugs claiming to contain semaglutide that are not FDA approved. Press release. Nov. 30, 2023. Accessed Dec. 14, 2023 at https://www.novomedlink.com/content/dam/novomedlink/semaglutide/November-30-2023-Company-Statement.pdf
Read next
Wegovy vs Ozempic: Which is Right for You?
Both Wegovy and Ozempic contain semaglutide, but Wegovy is prescribed for long-term weight management while Ozempic is used to control blood sugar levels in type 2 diabetes and help protect kidney function. They both lower the risk for heart-related complications, but they differ in other approved uses, doses, target populations and costs. Continue reading
How long to see weight loss results with Wegovy?
Weight loss may begin within the first 4 weeks of treatment with Wegovy, but the full effects of Wegovy may not be seen for several months or longer. In studies, after 68 weeks, 83% of people taking Wegovy lost 5% or more of their weight compared to 31% of people taking a placebo. Continue reading
Do Ozempic, Wegovy, Mounjaro & Zepbound cause hair loss?
There’s no evidence that hair loss is a direct side effect of Ozempic, Wegovy, Mounjaro or Zepbound. Hair loss is more likely due to the stress of rapid weight loss on your body, which can lead to temporary shedding of hair over several months, a condition known as telogen effluvium. Continue reading
Related medical questions
- How do Zepbound and Wegovy compare?
- Does Ozempic cause muscle loss and how to prevent it?
- Ozempic Face: What causes it and how to prevent it?
- How do you get Wegovy covered by insurance?
- Do GLP-1 drugs like Ozempic or Wegovy affect bone density?
- When is the best time of day to take Wegovy?
- Can you just stop taking Rybelsus?
- Is Ozempic covered by Medicare and Medicaid?
- What is the cost of Wegovy?
- Does Wegovy make you pee a lot or urine smell?
- How does Wegovy work for weight loss?
- Is Wegovy covered by Medicare?
- Saxenda vs Wegovy: Which weight loss drug is right for you?
- Can Ozempic and Wegovy cause eye blindness?
- Can Wegovy or Ozempic be used for heart failure?
- Semaglutide and liraglutide for alcohol use disorder (AUD)
- Wegovy coupon card: Do I qualify and how much can I save?
- What options are there for weight loss medications?
- What's the buzz on Ozempic and Wegovy?
- Zepbound Vs Mounjaro: Complete Comparison Guide for Weight Loss and Diabetes Treatment
- Why am I not losing weight on Mounjaro?
- How much is Zepbound with or without insurance?
- How long does it take for Zepbound to work?
- Is Zepbound covered by insurance?
- How much weight can I lose on Zepbound?
- What happens when you stop taking Zepbound?
- How does Zepbound help treat sleep apnea?
- How do I know if I have sleep apnea? The warning signs
- How do you inject / administer Zepbound?
- What is the Zepbound Coupon or Savings Card?
Drug information
Related support groups
- Wegovy (46 questions, 113 members)
- Zepbound (19 questions, 24 members)
- Mounjaro (49 questions, 121 members)
- Tirzepatide (15 questions, 13 members)
- Diabetes, Type 2 (500 questions, 1,426 members)
- Weight Loss (Obesity/Overweight) (848 questions, 1,508 members)
- Cardiovascular Risk Reduction (98 questions, 28 members)
- Obstructive Sleep Apnea/Hypopnea Syndrome (27 questions, 56 members)
- Sleep Apnea (19 questions, 102 members)